The invention relates to fused cyclooctyne compounds, and to a method for their preparation. The invention also relates to a conjugate wherein a fused cyclooctyne compound according to the invention is conjugated to a label, and to the use of these conjugates in bioorthogonal labeling, imaging and/or modification, such as for example surface modification, of a target molecule. The invention further relates to a method for the modification of a target molecule, wherein a conjugate according to the invention is reacted with a compound comprising a 1,3-dipole or a 1,3-(hetero)diene.

The present invention relates to compounds of formula (I): ##STR00001##
or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.

The present invention relates to compounds of formula (I): ##STR00001##
or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.

The present application provides a compound of Formula (A), or a pharmaceutically acceptable salt thereof, wherein R.sup.1, L.sup.1, n, L.sup.2, m, L.sup.3, p, Y.sup.2, and Y.sup.3 are as described herein. Methods of using the compound of Formula (A) to prepare an antibody conjugate, and methods of using these conjugates for cellular imaging are also described.

##STR00001##

An object of the present invention is to provide a composition for lithography capable of obtaining a film in contact with a resist layer or an underlayer film capable of forming a pattern excellent in exposure sensitivity the like. The object can be achieved by a composition for lithography containing a compound having at least one element selected from the group consisting of iodine, tellurium, and fluorine, or a resin having a constituent unit derived from the compound, wherein a total mass of the atoms in the compound is 15% by mass or more and 75% by mass or less.

Provided herein are compounds, compositions, kits, uses, and methods for assessing the viability of cells and/or quantifying the amount of live and dead cells in a mixture using differential stains. In some embodiments, the compounds are used in culture media or can function independently of fixation and/or permeabilization. In some embodiments, the compounds comprise a platinum atom. In some embodiments, the compounds comprise a nitrogen mustard moiety.

Provided herein are compounds, compositions, kits, uses, and methods for assessing the viability of cells and/or quantifying the amount of live and dead cells in a mixture using differential stains. In some embodiments, the compounds are used in culture media or can function independently of fixation and/or permeabilization. In some embodiments, the compounds comprise a platinum atom. In some embodiments, the compounds comprise a nitrogen mustard moiety.

An organic EL device includes a first emitting layer and a second emitting layer, in which the first emitting layer contains a first host material, the second emitting layer contains a second host material, the first and the second host material are mutually different, the first emitting layer and the second emitting layer at least contains a compound that emits fluorescence having a main peak wavelength of 500 nm or less, respectively, the compound contained in the first emitting layer and that emits fluorescence having a main peak wavelength of 500 nm or less is the same as or different from the compound contained in the second emitting layer, and a triplet energy T.sub.1(H1) of the first host material and a triplet energy T.sub.1(H2) of the second host material satisfy a numerical formula (Numerical Formula 1),

T.sub.1(H1)>T.sub.1(H2)  (Numerical Formula 1).

An organic EL device includes a first emitting layer and a second emitting layer, in which the first emitting layer contains a first host material, the second emitting layer contains a second host material, the first and the second host material are mutually different, the first emitting layer and the second emitting layer at least contains a compound that emits fluorescence having a main peak wavelength of 500 nm or less, respectively, the compound contained in the first emitting layer and that emits fluorescence having a main peak wavelength of 500 nm or less is the same as or different from the compound contained in the second emitting layer, and a triplet energy T.sub.1(H1) of the first host material and a triplet energy T.sub.1(H2) of the second host material satisfy a numerical formula (Numerical Formula 1),

T.sub.1(H1)>T.sub.1(H2)  (Numerical Formula 1).

An organic electroluminescence device includes an anode, a cathode, a first emitting layer, and a second emitting layer provided between the first emitting layer and the cathode, in which the first emitting layer includes, as a first host material, a first compound that includes at least one group represented by a formula (11) below, the first compound being represented by a formula (1) below, the second emitting layer includes a second compound represented by a formula (2A) below as a second host material, and the first emitting layer is in direct contact with the second emitting layer.

##STR00001##